Table 2

Accruing clinical trials combining radiosensitizing agents with radiation therapy
Trial description Sponsor Status
Sunitinib with hormonal ablation in patients with localized prostate cancer MD Anderson Cancer Center Ongoing, not recruiting
SU5416 with hormonal ablation in patients with localized prostate cancer University of Chicago Unknown
Everolimus with hormonal ablation in patients with high risk localized prostate cancer University of Michigan Not yet open
TAK-700 with hormonal ablation in patients with high risk localized prostate cancer Radiation Therapy Oncology Group Recruiting
Everolimus with hormonal ablation in patients with high risk locally advanced prostate cancer Centre Val d’Aurelle – Paul Lamarque Recruiting
Bevacizumab with hormonal ablation in patients with high risk localized prostate cancer Benaroya Research Institute Completed
Everolimus for salvage treatment of biochemical recurrence after prostatectomy Abramson Cancer Center of the University of Pennsylvania Recruiting
IL-12 gene therapy Baylor College of Medicine Completed
ProstAtak™ in patients with localized prostate cancer Advantagene, Inc. Recruiting
Isoflavones in patients with localized prostate cancer Barbara Ann Karmanos Cancer Institute Completed
Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer University of Alabama Completed
Selenomethionine in patients with localized prostate cancer Roswell Park Cancer Center Withdrawn
R-Flubiprofen in patients with high risk localized prostate cancer Myrexis Inc. Unknown
Panobinostat in patients with localized prostate cancer Novartis Pharmaceuticals Completed

Palacios et al.

Palacios et al. BMC Urology 2013 13:4   doi:10.1186/1471-2490-13-4

Open Data